The Bond Market Has the Blues, Oil Breaks to the Upside and Moderna to the Downside
Source: Ron Struthers  (8/7/23)
The long end of the bond market is starting to price in sticky inflation, and Ron Struthers of Struthers' Stock Reports expects interest rates to rise further. Higher energy prices will start adding to inflation again, adding to the problem. Moderna has broken down on the chart and will be reporting red ink in the next few years. Time to go short. More >

Biotech Co. An Attractive Investment
Source: Clive Maund  (8/4/23)
Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you why he believes it is an attractive investment. More >

Telehealth Co. Continues To See Soaring Revenues
Source: Streetwise Reports  (8/2/23)
This telemedicine company just had its first profitable quarter, and now it could see revenues double twice over two fiscal years. More >

Co. Works to Strengthen Itself After Merger Ended
Source: Scott Fortune  (8/2/23)
Its efforts include restructuring debt and divesting assets, noted a ROTH Capital Partners report. More >

Merger Between Two Firms Called Off
Source: Scott Fortune  (8/2/23)
The deal broke down because the parties could not sell assets that had to be divested for it to go through, noted a ROTH Capital Partners report. More >

Co. Starts Using AI on Its Telehealth Platform
Source: Streetwise Reports  (7/21/23)
This telehealth company says it has started using artificial intelligence (AI) and machine learning (ML) with two of the clients on its platform. More >

Second Half of 2023 Is Catalyst Rich for This Biopharma Co.
Source: Patrick Trucchio  (7/19/23)
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report. More >

Top Pick Healthcare Technology Co. Trading at Deep Discount
Source: Rob Goff  (7/19/23)
The healthcare tech firm's shares are underperforming despite two consecutive record quarters and a "landmark" contract win, noted an Echelon Capital Markets report. More >

Healthcare Tech Firm Sells Noncore Assets for $6M
Source: Rob Goff  (7/10/23)
The resulting upfront valuation gain equates to an estimated $0.02 per share, noted an Echelon Capital Markets report. More >

Approval Sought in Japan for New SARS-CoV-2 Vaccine
Source: Ed Arce  (7/7/23)
The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report. More >

Co. Addresses Opioid Crisis Through Novel Platforms
Source: Boobalan Pachaiyappan  (7/7/23)
This California biotech, developing products that prevent opioid abuse and overdose, gained coverage by an H.C. Wainwright & Co. analyst, an initiation report noted. More >

Up to 10,000 Patients To Join Telehealth Co.s Platform in Mexico
Source: Streetwise Reports  (7/6/23)
This company is expanding its telehealth platform into Mexico, where more than 10,000 new patients are expected to be on board by next June. More >

New Psoriasis Drug Shown More Effective Than On-Market One
Source: Julian Harrison   (7/6/23)
Recent clinical trial results show the oral interleukin-23 receptor to be a "cleaner" target than non-receptor tyrosine kinase 2, noted a BTIG report. More >

Co. With Alzheimer's App 'Meaningfully Undervalued,' Analyst Says
Source: Stefan Quenneville  (7/5/23)
Despite having revenues below expectations, one analyst says this health company's Alzheimer's dementia diagnosis app is gaining commercial traction. More >

Biotech Co. Remains Opportunity for Those With High Risk Tolerance
Source: Stefan Quenneville  (6/30/23)
Recently, Antibe Therapeutics released its fiscal 2023 year-end (FQ423) results, which remained inline with expectations, noted an Echelon Capital research note. More >

Q3: Chen Is Still Bullish on This Precious Metal
Source: Streetwise Reports  (6/29/23)
Asset manager Chen Lin continues to rely heavily on this precious metal. Find out his top picks for the third quarter of 2023. More >

Telehealth Co. Expands to More Patients, Picks Up Coverage
Source: Streetwise Reports  (6/26/23)
Reliq Health Technologies Inc. continues to pick up more contracts with skilled nursing facilities (SNFs) and other health care groups. Now it also has gotten analyst attention. More >

New Drug for Bone Growth Disorder Improves Height Velocity
Source: Dr. Thomas Shrader  (6/21/23)
Phase 2 trial data at six months are positive in children with achondroplasia, noted a BTIG report. More >

Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries
Source: Streetwise Reports  (6/16/23)
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream. More >

777% Gain Implied in Analyst's Target Price on Biopharma Co.
Source: Dr. Yi Chen  (6/14/23)
Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report. More >

Telehealth Co. Expands With Six New Contracts in Three States
Source: Streetwise Reports  (6/13/23)
New contracts are expected to add more than 3,000 new patients to Reliq Health Technologies Inc.'s platform by the first quarter of next year, the company said. More >

Court Grants Firm Protection From Creditors
Source: Andrew Semple  (6/12/23)
Despite this development, there are still some ways this Canadian retailer-distributor could salvage some value for shareholders, noted an Echelon Capital Markets report. More >

Biotech Co. To Exit Health Care Services
Source: Streetwise Reports  (6/12/23)
Friday, Awakn Life Sciences Corp. announced it would be taking focus away from healthcare services and instead concentrate its efforts exclusively on research and development for therapeutics for addiction treatment. Read more to learn what the global addiction treatment market looks like and where the company is headed in the future. More >

Key Catalyst for US Biopharma Stock on Track for Q4/23
Source: Ed Arce  (6/9/23)
Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report. More >

Medical Device Co. Completes Merger in Q1/23
Source: Jeffrey Cohen  (6/8/23)
Due to the acquisition, the U.S.-based firm generated 844% more revenue during the quarter than it did a year earlier, noted a Ladenburg Thalmann report. More >